The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis - 30/05/20

pages | 11 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | A great number of lncRNAs are dysregulated in osteosarcoma. |
• | LncRNAs are implicated many tumorigenic signaling pathways. |
• | LncRNAs can be served as therapeutic targets and predictors of prognosis. |
Abstract |
Osteosarcoma is a bone tumor prevalent in children and young adults. LncRNAs are a family of non-protein-coding transcripts longer than 200 nucleotides. The tumor-related pathological functions of lncRNAs include proliferation, migration, and chemotherapy resistance, all of which have been widely acknowledged in research on osteosarcoma. In addition, compelling evidence suggests that lncRNAs could serve as diagnostic indicators, prognostic biomarkers, and targets for disease treatment. In this review, we systematically summarize how lncRNAs regulate tumorigenesis, invasion and therapeutic resistance. By deepening our knowledge of the relationship between lncRNAs and osteosarcoma, we hope to translate research findings into clinical applications as soon as possible.
Le texte complet de cet article est disponible en PDF.Abbreviations : lncRNA, sncRNA, PD-1, ncRNA, ceRNA, miRNA, Hh, MTX, HULC, MALAT1, AMOT, NBAT1, TUG1, HIF-2α, HIF2PUT, TUSC7, ROC, MEG3, ABC, ODRUL, ABCB1, CYP, GST, UGT, GSTP1, Casp8ap2, AIFM3, CR, MRP1, P-gp, Shh, Ihh, Dhh, PTCH, Smo, YAP1, GSK3β, LRP, Wif1, FRZB, DKK3, Dvl, APC, JAG, DLL, NECD, NICDNotch, ADAM, TMD
Keywords : Long noncoding RNA, Osteosarcoma, Signaling pathways, Resistance, Prognosis
Plan
Vol 127
Article 110141- juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?